TITLE: Imiquimod for the Treatment of External Genital Warts in Adults: Clinical and Cost-effectiveness

DATE: 07 December 2012

RESEARCH QUESTIONS

1. What is the clinical evidence of the benefits and harms of 5% imiquimod for the treatment of external genital warts?

2. What is the evidence of the cost-effectiveness of 5% imiquimod for the treatment of external genital warts

KEY MESSAGE

One systematic review, two meta-analyses, three randomized controlled trials, three non-randomized studies, and two economic evaluations were identified regarding the clinical evidence of the benefits and harms or the cost-effectiveness of 5% imiquimod for the treatment of external genital warts.

METHODS

A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2012, Issue 11), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No methodological filters were applied to limit retrieval by publication type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2004 and November 28, 2012. Internet links were provided, where available.

RESULTS

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are
presented first. These are followed by randomized controlled trials, non-randomized studies, and economic evaluations.

One systematic review, two meta-analyses, three randomized controlled trials, three non-randomized studies, and two economic evaluations were identified regarding the clinical evidence of the benefits and harms or the cost-effectiveness of 5% imiquimod for the treatment of external genital warts. Additional references of potential interest are provided in the appendix.

**Health Technology Assessments**
No literature identified.

**Systematic Reviews and Meta-analyses**


**Randomized Controlled Trials**


**Non-Randomized Studies**


Economic Evaluations


PREPARED BY:
Canadian Agency for Drugs and Technologies in Health
Tel: 1-866-898-8439
www.cadth.ca
APPENDIX – FURTHER INFORMATION:

Randomized Controlled Trials – Imiquimod at doses other than 5%


Non-Randomized Studies – Special Patient Groups


Review Articles


Additional References


